Dietary Supplementation With Butyrate in Individuals With Liver Steatosis and Metabolic Syndrome

Dietary Supplementation With Butyrate in Individuals With Liver Steatosis and Metabolic Syndrome: a Randomized Double-blind Placebo-controlled Clinical Trial

This was a double-blind, randomized, placebo-controlled clinical study aiming to assess the effect of a food for special medical purposes with functional release containing calcium butyrate, zinc gluconate and vitamin D3 on liver steatosis in individuals with NAFLD and metabolic syndrome

Inclusion criteria:

• 40-75 years of age
• Caucasian ethnicity
• NAFLD
• Metabolic Syndrome

Exclusion criteria:

• acute and chronic gastrointestinal disorder not controlled by stable treatment since at least 3 months
• serious or disabling diseases (e.g. severe organ failure, malignancy or dementia)
• obesity (body mass index (BMI)> 30 Kg/m2)
• type 1 and 2 diabetes
• alcoholism
• pregnancy and breastfeeding
• any medical or surgical condition making complex or inconstant the adhesion to the study protocol